Lifotronic(SH:688389)2024-10-28 10:08Financial Performance - The company's operating revenue for the first three quarters of 2024 reached 857 million yuan, representing a year-on-year growth of 5.89%[20] - The net profit attributable to shareholders for the same period was 257 million yuan, with a year-on-year increase of 25.62%[20] - In Q3 2024, the operating revenue was 267 million yuan, showing a year-on-year growth of 6.45%[21] - The gross profit margin stood at 69.89%, while the net profit margin was 29.89%[12][14] - The net cash flow from operating activities increased by 42.78% year-on-year, reaching 253 million yuan[29] Research and Development - R&D investment for the first three quarters of 2024 amounted to 152 million yuan, reflecting a year-on-year increase of 9.51%, which is 17.73% of operating revenue[26] - The company has obtained a total of 218 valid patents, including 55 invention patents, as of September 30, 2024[26] - The company launched a new generation of double antibody sandwich 25-hydroxyvitamin D assay kit and a bronchoscopic visual soft mirror, marking significant advancements in product development[26] Expansion and Incentives - The company established a subsidiary in Russia in July 2024, enhancing its global presence[27] - The company plans to grant 11.31 million stock options to 186 key personnel as part of its 2024 stock option incentive plan[28]